mvt-2163
mAbexperimentalImaging agent
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2016 (NCT02687230)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Lewis Y antigenImmunity, passive
Lewis Y antigen immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
- Imaging
- 89-Zirconium
Oral
No
Parenteral
No
Topical
No
Also known as
- mvt-2163
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04883775 | Phase 1 | May 10, 2021 | Biontech, Memorial Sloan-Kettering Cancer Center |
| NCT02687230 | Phase 1 | Jul 1, 2016 | MabVax Therapeutics, Inc., SciQuus Oncology |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biontech | For profit | 1 | 0 | 1 | 2021 |
| MabVax Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2016 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2021 |
| SciQuus Oncology | For profit | 1 | 0 | 1 | 2016 |
4 organizations
Page 1 / 1